Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

2.

Pickleball program boosts health and wellness for cancer survivors, study finds

3.

Medical Journal March 28, 2023

4.

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

5.

New opportunities for screening and treatment have been created by the identification of the genetic drivers of esophageal cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot